The influence of smoking on the clinical effects of a one-year program of physical rehabilitation of patients of working age who underwent acute myocardial infarction


Cite item

Full Text

Abstract

Purpose. Study of the clinical effectiveness of a long-term (one-year) physical rehabilitation program with the inclusion of physical training (PT) in the III (polyclinic) stage of cardiac rehabilitation in patients with ischemic heart disease of working age who underwent acute myocardial infarction (AMI), depending on the status of smoking. Materials and methods. The study included men (n = 241, mean age 51.3 ± 2.2 years) who underwent AMI (no earlier than 3 weeks from the event). Patients were randomized into 2 groups: the main ("O") - 126 people and the control ("K") - 115 participants. All patients received standard medication. In the "O" group, PT was used in the medium intensity regime (50-60% of the fulfilled capacity with a load sample) 3 times a week for one year. Each of the groups was divided into two subgroups, depending on the status of smoking. Effectiveness of the effect was assessed by clinical data and results of instrumental-laboratory analysis. Results. After a yearly PT, a significant increase in physical performance was observed in smokers (n=41) and nonsmokers (n=41) and nonsmokers (n=85) after IMI: an increase in the duration of the load (by 30.3%, p<0.001 and 28.4%, p<0.001) and its power (by 31.2%, p<0.001 and 30.8%, p<0.001) against the backdrop of an increase (by 3.8%, p<0.01) in the economics of physical work, but only for smokers. In the absence of PT, only in nonsmokers (n=72) after AMI, there was an increase in the duration of the load (by 10.1%, p<0.01) and its power (by 11.1%, p<0.05), but to a lesser extent than non-smoking trained patients. In smoking patients (n=43), in the absence of PT, there was no change in the Fed indicators, on the contrary, there was a decrease in the cost-effectiveness of the work performed (by 13.3%, p<0.05). The level of daily motor activity increased only against the background of PT among smokers by 22.2% (p<0.001) and non-smokers by 19.4% (p<0.01). This was combined with a decrease in heart size and increased contractility of the left ventricular myocardium in smokers and non-smokers, but more pronounced positive changes in the background of PT were seen in non-smoking patients. There was no positive dynamics of echocardiographic parameters in the absence of PT, although a slight increase (by 1.9%, p<0.05) of the left ventricular ejection fraction was observed in nonsmokers. Only in the background of PT, smoking and non-smoking patients (equally) had a decrease in the levels of atherogenic lipids and an increase in the concentration of high-density lipoprotein cholesterol by 18.2% (p<0.05) and 20% (p<0.05), respectively. In smoking patients without PT, on the contrary, there was an increase (by 12.5%, p<0.05) of the level of triglycerides. PT had anti-ischemic effects, manifested in a reduction in angina attacks and the need for nitroglycerin consumftion in smokers and non-smokers, in contrast to untrained patients. After the year of PT, the development of all cases of cardiovascular complications significantly decreased in the subgroup of smokers by 44.8% (p<0.05) and the non-smoking group by 50.9% (p<0.05), and the number of days of temporary incapacity for work Per patient decreased by 2 days for smokers and 2.6 days for non-smokers. The conclusion. Long-term (annual) PT of medium intensity at the third outpatient stage of cardiac rehabilitation in both smokers and non-smokers who underwent AMI provides a stable course of the disease, reduces the likelihood of developing cardiovascular complications, improves the patient's quality of life and is safe in the vast majority. At the same time, smoking should be considered as a factor that reduces the rehabilitation potential of the patient who has undergone AMI and prevents better results in cardiac rehabilitation.

About the authors

M. G Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза ФГБУ НМИЦ ПМ 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

D. M Aronov

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. лаб. кардиологической реабилитации ФГБУ НМИЦ ПМ, засл. деятель науки РФ 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

V. B Krasnitskii

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

канд. мед. наук, вед. науч. сотр. лаб. кардиологической реабилитации отд. реабилитации и вторичной профилактики сочетанной патологии ФГБУ НМИЦ ПМ 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Россия 2014. Стат. справочник. Р76 Росстат. М., 2014.
  2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028-34.
  3. Mathers C.D, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2011; 3: e442.
  4. Аронов Д.М., Красницкий В.Б., Бубнова М.Г. и др. Влияние физических тренировок на физическую работоспособность, гемодинамику, липиды крови, клиническое течение и прогноз у больных ишемической болезнью сердца после острых коронарных событий при комплексной реабилитации и вторичной профилактики на амбулаторно - поликлиническом этапе (Российское кооперативное исследование). Кардиология. 2009; 3: 49-56.
  5. Lawler P.R, Filion K.B, Eisenberg M.J. Efficacy of Exercise - Based Cardiac Rehabilitation Post-Myocardial Infarction: A Systematic Review and Meta - Analysis of Randomized Controlled Trials. Am Heart J 2011; 162: 571-84. http://dx.doi.org/10.1016/j.ahj.2011.07.017
  6. Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post - myocardial infarction patients: nationwide real world data demonstrate the importance of a long - term perspective. Eur Heart J 2015; 36: 1163-70.
  7. Alnasser S.M, Huang W, Gore J.M et al. Late consequences of acute coronary syndromes: global registry of acute coronary events (GRACE) follow - up. Am J Med 2015; 128: 766-75.
  8. Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Люберецкое исследование смертности (исследование ЛИС): факторы, влияющие на отдаленный прогноз жизни после перенесенного инфаркта миокарда. Профилактическая медицина. 2013; 2: 32-8.
  9. González-Pacheco H, Vargas-Barrón J, Vallejo M et al. Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. Ther Clin Risk Management 2014; 10: 815-23.
  10. Khot U.N, Khot M.B, Bajzer C.T et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290 (7): 898-904.
  11. Weintraub W.S, Klein L.W, Seelaus P.A et al. Importance of total life consumftion of cigarettes as a risk factor for coronary artery disease. Am J Cardiol 1985; 55: 669-72.
  12. Waters D, Lesperance J, Gladstone P et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996; 94: 614-21.
  13. Hasdai D, Garratt K.N, Grill D.E et al. Effect of smoking status on the long - term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336: 755-61.
  14. Gambardella J, Sardu C, Sacra C, Santulli G. Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis 2017; 257: 242-5. http://dx.doi.org/10.1016/j.atherosclerosis.2016.12.010
  15. Красницкий В.Б., Аронов Д.М., Джанхотов С.О. Изучение физической активности у больных ИБС с помощью специализированного Опросника Двигательной Активности «ОДА-23+». Кардиоваскулярная терапия и профилактика. 2011; 8: 90-7.
  16. Гладков А.Г., Зайцев В.П., Аронов Д.М., Шарфнадель М.Г. Оценка качества жизни больных с сердечно - сосудистыми заболеваниями. Кардиология. 1982; 2: 100-3.
  17. Zieske A.W, Takei H, Fallon K.B, Strong J.P. Smoking and atherosclerosis in youth. Atherosclerosis 1999; 144: 403-8.
  18. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol 2013; 10: 219-30.
  19. Ambrose J.A, Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43: 1731-7.
  20. Аронов Д.М. Современные представления о влиянии курения на сердечно - сосудистую систему. Тер. архив. 1978; 4: 117-26.
  21. Barreiro E, del Puerto-Nevado L, Puig-Vilanova E et al. Cigarette smoke - induced oxidative stress in skeletal muscles of mice. Respir Physiol Neurobiol 2012; 182 (1): 9-17.
  22. Liu Q, Xu W.G, Luo Y et al. Cigarette smoke - induced skeletal muscle atrophy is associated with up - regulation of USP-19 via p38 and ERK MAPKs. J Cell Biochem 2011; 112 (9): 2307-16.
  23. Rinaldi M, Maes K, de Vleeschauwer S et al. Long - term nose - only cigarette smoke exposure induces emphysema and mild skeletal muscle dysfunction in mice. Dis Model Mech 2012; 5 (3): 333-41.
  24. Rivers J.T, White H.D, Cross D.B. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative managemint: incident and effect of smoking. J Am Coll Cardiol 1990; 16: 340-8.
  25. Аронов Д.М., Бубнова М.Г., Барбараш О.Л. и др. Российские клинические рекомендации «Острый инфаркт миокарда с подъемом сегмента ST на ЭКГ: реабилитация и вторичная профилактика» (2014 г., по поручению Минздрава России, утверждены профессиональными сообществами). CardioСоматика. 2014; с. 4-42.
  26. Frey P, Waters D.D, De Micco D.A. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011; 107: 145-50.
  27. Sturchio A, Gianni A.D, Campana B et al. Coronary Artery RIsk MAnagement Programme (CARIMAP) Delivered by a Rehabilitation Day - Hospital. J Cardiopulmonary Rehabilitation Prevention 2012; 32: 386-93.
  28. Prugger Ch, Wellmann J, Heidrich J et al. on behalf of the EUROASPIRE Study Group. Passive smoking and smoking cessation among Patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur Heart J 2014; 35: 590-8. doi: 10.1093/eurheartj/eht538.
  29. Bustamante M.J, Valentino G, Krämer V et al. Patient Adherence to a Cardiovascular Rehabilitation Program: What Factors Are Involved? Int J Clin Med 2015; 6: 605-14.
  30. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и др. (от имени исследователей). Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование «ПЕРСПЕКТИВА» (часть I). Кардиоваскулярная терапия и профилактика. 2010; 6: 47-56.
  31. Piepoli M.F, Hoes A.W, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315-81 doi: 10.1093/eurheartj/ehw106.
  32. Бокерия Л.А., Аронов Д.М., Барбараш О.Л. и др. Российские клинические рекомендации. Коронарное шунтирование больных ишемической болезнью сердца: реабилитация и вторичная профилактика // CardioСоматика. 2016; 3-4: 5-71.
  33. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta - analysis. Cochrane Database of Systematic Reviews. The Cochrane Collaboration and published in The Cochrane Library 2013, Issue 5: CD009329.doi: 10.1002/14651858.CD009329.pub2.
  34. Vadasz I. The first Hungarian experiences with varenicline to support smoking cessation. Medicina Thoracalis 2009; LXII. 1: 1-9.
  35. Anthenelli R.M, Benowitz N.L, West R et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double - blind, randomised, placebo - controlled clinical trial. Lancet 2016; 387: 2507-20.
  36. Eisenberg M.J, Windle S.B, Roy N et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation 2015. doi: 10.1161/CIRCULATIONAHA.115. 019634.
  37. Rigotti N.A, Pipe A.L, Benowitzm N.L et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221-9.
  38. Prochaska J.J, Hilton J.F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta - analysis. BMJ 2012; 344: e2856. doi: 10.1136/bmj.e2856.

Copyright (c) 2017 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies